Skip to content

Database release

This release covers the 41 pull requests merged between 2026-05-08 and 2026-10-29, and is a formal launch of a 2.0.0 state of moalmanac-db. It adds 60 indications: 9 from FDA, 22 from EMA, 14 from Health Canada (HC), and 15 from the Health Service Executive (HSE). Over the same period, the relational database in referenced/ was rebuilt to align more closely with GA4GH VA-Spec, VRS, and Cat-VRS, and the database content is now licensed under CC BY 4.0.

View on GitHub

Database content updates

Added entries

Revised entries

Removed entries

  • (HSE) 18 HSE indications were marked Withdrawn in the 2026-08-02 HSE update, and their statements were deprecated: ind:hse:00200:a, 00200:b, 00215:e, 00215:g, 00225:c, 00253:a, 00253:b, 00254:a, 00254:b, 00254:c, 00328:a, 00335:a, 00335:b, 00361:a, 00361:b, 00397:a, 00430:a, and 00506:a. The records were kept, not deleted.

Feature updates

Repository and schema changes in this release:

  • Concept identifiers. Integer primary and foreign keys were replaced with structured, self-describing strings, for example stmt:fda:tevimbra:1:0 and prop:vtxr:0 (Issue 51). Dereferenced per-concept files now use _ instead of : in their file names, so they work on Windows.
  • Indications as Information Entities. Indications now follow VA-Spec's Information Entity model: each one has its own contributions, reportedIn documents, and a superseded_by list. Dereferenced indications carry their statement description as an extension.
  • Status. Every document, indication, and statement now has a status. Statement status is propagated from the indication: Approved or Accelerated gives Active, Superseded gives Superseded, and Withdrawn gives Deprecated. Statements now hold status and indication as extensions, per the VA-Spec Statement model.
  • Biomarkers. Biomarkers were refactored to align with VRS and Cat-VRS. A new biomarker criteria table pairs each biomarker with a present flag. Biomarkers now dereference to Defining Allele, Copy Change, Function, Feature Context, Adjacency, and Defining Location constraints. New tables hold VRS alleles, sequence references, and sequence locations for curated genes' MANE Select transcripts, protein products, exons, chromosome arms, and whole chromosomes. Cat-VRS does not yet support sets of categorical variants, so subjectVariant is a placeholder and the biomarkers are carried as an extension.
  • JSON schemas. Schemas were added for both the referenced and dereferenced records and are checked by the test suite. Extensions were removed from referenced/ records, except biomarkers, to fit the API's SQLite databases. Gene fusions and translocations are now biomarker types of their own.
  • Codings. The NCI Thesaurus is now the primary coding for diseases, with mappings to OncoTree (updated to the 2025-10-03 release). SNOMED mappings were removed. Scripts were added to download the NCI Thesaurus, OncoTree, and RefSeq.
  • Documents. Each FDA label now has a dated document record alongside the evergreen one, and each FDA indication links to both its current label and the label that first approved it. identification_number was renamed to regulatory_identifier, and FDA values are now prefixed application numbers such as NDA207103. company is now nullable.
  • Licensing and documentation. The database content is now licensed under CC BY 4.0. The scripts in utils/ and tests/ remain under GPL v2. A contributing guide, a Development section in the README, and a revised pull request template were added. The environment now uses Python 3.14.

Implementation details

  • Evergreen FDA documents and label URLs were updated for Bizengri (2026-05-08), Enhertu (2026-05-15), Ibrance (2026-06-24), Trodelvy (2026-06-24), and Truqap (the label revised in September 2026), and documents were added for Veppanu. doc:hse:00414 is Active again and points to the corrected 2026-08-11 regimen. HPRA documents for Arimidex, Aromasin, and Femara gained regulatory identifiers.
  • Documents grew from 415 to 1,605 and URLs from 694 to 1,890, mostly from the dated FDA label history. Contributions grew from 57 to 558 as approval, supersession, and curation events were recorded on each indication.
  • Indications grew from 842 to 902, and statements from 1,895 to 2,072. Of the statements, 55 are now Deprecated and 6 are Superseded.
  • A total of 80 propositions (prop:vtxr:546 and prop:vtxr:915 through prop:vtxr:995) and 27 therapy groups (txgrp:198 through txgrp:224) were added, and 15 duplicate propositions were removed. Several of the new propositions have no statements yet and were added for upcoming UK NICE curation, for example fruquintinib for KRAS and NRAS wild-type colorectal cancer, tebentafusp for HLA-A*02:01 uveal melanoma, and rucaparib and niraparib for ovarian cancers with or without HRD or BRCA1/2 variants.
  • Seven therapies were added: aumolertinib, camizestrant, dexamethasone, fruquintinib, obinutuzumab, tebentafusp, and vepdegestrant.
  • Six biomarkers were added: CCND1 overexpression, HLA-A*02:01, PD-L1 < 1% IC, PD-L1 > 0%, PTEN-deficient, and t(11;14). The AKT1 and PIK3CA "somatic variants" biomarkers were renamed to "oncogenic variants". EZH2 p.A862G and H3-3A p.K27M are now named EZH2 p.A682G and H3-3A p.K28M.
  • Diseases were renamed or consolidated as part of the move to NCI Thesaurus codings. For example, "Acute Lymphoid Leukemia" is now "Acute Lymphoblastic Leukemia", "Acute Promyelocytic Leukemia with PML::RARA" is now "Acute Promyelocytic Leukemia", and "Low-Grade Glioma, NOS" is now "Low-Grade Glioma". Anaplastic large cell lymphoma is no longer marked as a solid tumor. Mantle Cell Lymphoma and Differentiated Thyroid Gland Carcinoma were added.
  • Eight new HC indications do not have derived statements yet: ind:hc:piqray:1, ind:hc:sprycel:3 through :5, and ind:hc:tasigna:4 through :7.
  • Agent last-updated dates are FDA 2026-06-24, EMA 2026-08-02, HSE 2026-08-02, and HC 2026-05-22. referenced/about.json was last updated on 2026-10-28, with release 2.0.0.